Gene · 81607
Papers1,879
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1 to 20 of 1,879
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Nectin-4-Directed Therapeutic Repositioning Augments Antitumor Efficacy in Epithelial Ovarian Carcinoma. | Cancer Commun (Lond) | 2026 | 42819105 | PubTator, text mining | PubMed |
| Nectin-4-Targeted PET/CT Before Organ-Sacrificing Surgery for Occult Ureteral Carcinoma. | J Nucl Med | 2026 | 42816126 | PubTator, text mining | PubMed |
| Nectin4 as a Promising Target for CAR-NK Cell Therapy in Breast Cancer Treatment. | Front Biosci (Landmark Ed) | 2026 | 42811988 | PubTator, text mining | PubMed |
| Time to Rethink Pathology Reporting in Adenoid Cystic Carcinoma. | Head Neck | 2026 | 42811719 | PubTator, text mining | PubMed |
| Pretreatment Tumor NECTIN4 RNA Expression Is Associated with First-line Enfortumab Vedotin Plus Pembrolizumab Efficacy in Metastatic Urothelial Cancer. | Eur Urol | 2026 | 42786066 | PubTator, text mining | PubMed |
| NECTIN4, TROP2 and PDL1 in Breast Cancer: Immunohistochemical Profiling and Clinical Associations. | Int J Surg Pathol | 2026 | 42770457 | PubTator, text mining | PubMed |
| Beyond approval: a mechanism-based review of novel anti-tumour agents in cervical cancer and when to use them. | Front Immunol | 2026 | 42769609 | PubTator, text mining | PubMed |
| Enfortumab vedotin-related cutaneous toxicity: Clinical features, pathogenesis and management. | J Dermatol Sci | 2026 | 42754439 | PubTator, text mining | PubMed |
| Immunohistochemical stratification of bladder small cell carcinoma reveals two major phenotypes with distinct therapeutic biomarker profiles. | Histopathology | 2026 | 42747234 | PubTator, text mining | PubMed |
| Expression of nectin-4 in squamous cell carcinoma of prostate: a pilot study and case report. | Front Oncol | 2026 | 42740991 | PubTator, text mining | PubMed |
| Antibody-Mediated Therapies in Urothelial Carcinoma: A Critical Narrative Review. | Cancers (Basel) | 2026 | 42738266 | PubTator, text mining | PubMed |
| Integrated Analysis of HER2 Expression and ERBB2 Alterations in Bladder Cancer. | Cancer Sci | 2026 | 42732768 | PubTator, text mining | PubMed |
| Prognostic value and diagnostic performance of nectin-4-targeted [68Ga]Ga-FZ-NR-1 PET/CT versus [18F]FDG in recurrent or metastatic triple-negative breast cancer. | Eur J Nucl Med Mol Imaging | 2026 | 42730763 | PubTator, text mining | PubMed |
| Disease stage-dependent expression of ADC-related biomarkers in urothelial carcinoma. | Transl Androl Urol | 2026 | 42729159 | PubTator, text mining | PubMed |
| Target Antigen Identification for Antibody Drug Conjugate Therapy in Biliary Tract Cancer. | Clin Cancer Res | 2026 | 42720429 | PubTator, text mining | PubMed |
| Exposure-Response Analysis of Enfortumab Vedotin Plus Pembrolizumab as First-Line Therapy for Locally Advanced or Metastatic Urothelial Cancer. | Clin Pharmacol Ther | 2026 | 42717277 | PubTator, text mining | PubMed |
| Integrating NECTIN4 Amplification With Membranous Nectin-4 Expression to Develop a Scoring System for Predicting Enfortumab Vedotin Response in Urothelial Carcinoma. | Clin Cancer Res | 2026 | 42714834 | PubTator, text mining | PubMed |
| Dual-Target Nectin-4/FAP Heterobivalent Probe 68Ga/177Lu-FZ-NF-1 for Triple-Negative Breast Cancer: Preclinical Theranostic Evaluation and First-in-Human Translation. | Adv Sci (Weinh) | 2026 | 42711843 | PubTator, text mining | PubMed |
| Gemcitabine-Cisplatin Chemotherapy Induces Nectin-4 Downregulation and Enfortumab Vedotin Resistance in Bladder Cancer. | Eur Urol Oncol | 2026 | 42711240 | PubTator, text mining | PubMed |
| Payload-Free [89Zr]Zr-DFO*-sq-Enfortumab ImmunoPET for Imaging Nectin-4 Expression in Bladder Cancer. | Mol Pharm | 2026 | 42704134 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/81607/papers